Methoxyamine

Generic Name: Methoxyamine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: CH_₅NO

CAS Number: 67-62-9

Unique Ingredient Identifier: 9TZH4WY30J

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Stage III Lung Cancer AJCC v8
Lung Adenocarcinoma
Lung Large Cell Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Biological: Durvalumab
Procedure: FDG-Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Drug: Methoxyamine
Drug: Pemetrexed
Radiation: Radiation Therapy

First Posted Date: 2022-01-20

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT05198830

Locations: 🇺🇸
Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States
🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 19 locations

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Large Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Large Cell Carcinoma AJCC v7
Stage IV Lung Adenocarcinoma AJCC v7
Stage III Lung Adenocarcinoma AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Large Cell Carcinoma AJCC v7
Stage IIIA Lung Adenocarcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Methoxyamine
Drug: Methoxyamine Hydrochloride
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2022-06-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02535325

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1

Active, not recruiting

Conditions: Recurrent Pleural Malignant Mesothelioma
Unresectable Solid Neoplasm
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Advanced Peritoneal Malignant Mesothelioma
Advanced Pleural Malignant Mesothelioma
Recurrent Peritoneal Malignant Mesothelioma

Interventions: Drug: Methoxyamine
Drug: Cisplatin
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT02535312

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States

and more 11 locations

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

Phase 2

Terminated

Conditions: Adult Brain Glioblastoma

Interventions: Other: Treatment
Drug: Methoxyamine
Drug: Temozolomide

First Posted Date: 2015-03-24

Last Posted Date: 2019-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT02395692

Locations: 🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 9 locations

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma

Interventions: Drug: fludarabine phosphate
Drug: methoxyamine
Other: laboratory biomarker analysis
Other: pharmacological study
Genetic: western blotting
Other: mass spectrometry
Genetic: DNA analysis

First Posted Date: 2012-08-07

Last Posted Date: 2015-08-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT01658319

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Methoxyamine
Drug: Temozolomide

First Posted Date: 2009-05-04

Last Posted Date: 2019-02-22

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 66

Registration Number: NCT00892385

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy